ReviewActa neurologica Scandinavica2022
Blood biomarkers in epilepsy.
Review in Acta neurologica Scandinavica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Serum Biomarkers of Brain Injury in Diagnosis of Patients After Seizure in Emergency Department: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Contemporary in vivo rodent electroconvulsive therapy (ECT) models in translational depression research: a systematic review.Translational psychiatry · 2025Pooled it
- A Systematic Review of the Predictive and Diagnostic Uses of Neuroinflammation Biomarkers for Epileptogenesis.International journal of molecular sciences · 2024Pooled it
- Interaction Between Peripheral Cytokines and Central Neuroinflammation in Temporal Lobe Epilepsy.CNS neuroscience & therapeutics · 2026Article
- Peripheral Inflammatory Biomarkers in Chronic Autoimmune-Associated Epilepsy: An Exploratory Case-Control Study.Biomolecules · 2026Observational
- Zonisamide nanodiamonds for brain targeting: A comprehensive study utilising in silico, in vitro, in vivo, and molecular investigation for successful nose-to-brain delivery for epilepsy management.Drug delivery and translational research · 2026Article
- Markers of Antiseizure Treatment Efficacy in Children: A Review.Journal of clinical medicine · 2026Review
- Artificial intelligence-based biomarkers for the diagnosis and treatment of neurological conditions: a narrative review.Molecular brain · 2026Review
- Neurodegeneration Biomarkers in Epilepsy: A Critical Review of Current Findings.Life (Basel, Switzerland) · 2026Review
- Vagus nerve stimulation: anti-inflammatory effects in epilepsy.Frontiers in human neuroscience · 2026Article
- Elevated serum plasminogen activator inhibitor-1 is associated with seizure burden, drug resistance, and neuroinflammatory markers in pediatric epilepsy.Frontiers in pediatrics · 2026Article
- Epileptogenesis in meningioma: Theories, putative biomarkers, and postoperative risk.Epilepsia · 2025Review
- Predictive value of traditional laboratory parameters and inflammatory indices for same-day seizure recurrence in patients with epileptic seizures.Epilepsia open · 2025Article
- A research roadmap for SCN8A-related disorders: addressing knowledge gaps and aligning research priorities across stakeholders.Orphanet journal of rare diseases · 2025Article
- The role of ubiquitin C-terminal hydrolase (UCH-L1) and protein S100B in differentiating patients with epileptic and psychogenic non-epileptic seizures - Pilot study.Epilepsia open · 2025Article
- Urinary Metabolic Profiling During Epileptogenesis in Rat Model of Lithium-Pilocarpine-Induced Temporal Lobe Epilepsy.Biomedicines · 2025Article
- High-resolution multimodal profiling of human epileptic brain activity via explanted depth electrodes.JCI insight · 2025Article
- Circulating microRNAs as Biomarkers of Various Forms of Epilepsy.Medical sciences (Basel, Switzerland) · 2025Article
- Brain injury biomarkers and applications in neurological diseases.Chinese medical journal · 2025Review
- Neurostimulation for the Management of Epilepsy: Advances in Targeted Therapy.Current drug targets · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robust and accessible biomarkers are greatly needed in epilepsy. Diagnostic and prognostic precision in the clinic needs to improve, and there is a need for objective quantification of seizure burden. In recent years, there have been advances in the development of accessible and cost-effective blood-based biomarkers in neurology, and these are increasingly studied in epilepsy. However, the field is in its infancy and specificity and sensitivity for most biomarkers in most clinical situations are not known. This review describes advancements regarding human blood biomarkers in epilepsy. Examples of biochemical markers that have been shown to have higher blood concentrations in study subjects with epilepsy include brain proteins like S100B or neuronal specific enolase, and neuroinflammatory proteins like interleukins, and tumor necrosis factor-alpha. Some of the blood biomarkers also seem to reflect seizure duration or frequency, and levels decrease in response to treatment with antiseizure medication. For most biomarkers, the literature contains seemingly conflicting results. This is to be expected in an emerging field and could reflect different study populations, sampling or analysis techniques, and epilepsy classification. More studies are needed with emphasis put on the classification of epilepsy and seizure types. More standardized reporting could perhaps decrease result heterogeneity and increase the potential for data sharing and subgroup analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.